Effects of sodium nitroprusside in the acute dizocilpine (MK-801) animal model of schizophrenia.
Schizophrenia treatment remains a major challenge, especially the associated cognitive impairments, as these are not consistently alleviated by conventional antipsychotics. Recent animal and clinical studies suggest that the nitric oxide (NO) donor sodium nitroprusside (SNP) reduces the psychiatric symptoms and cognitive deficits of schizophrenia. The present study was designed to investigate the efficacy of SNP against schizophrenia-like behavioral and cognitive deficits in the dizocilpine (MK-801) rat model. We used the rotarod and open field tests to identify the SNP dose which had no adverse effects on rat's exploratory and motor behavior, then established the schizophrenia model by injecting adult Sprague-Dawley rats intraperitoneally with MK-801 (0.4 mg/kg) with or without SNP pre-treatment. Behavioral changes were examined after 10 min. Prepulse inhibition (PPI) and the Y maze tests were conducted to assess cognitive deficits, and elevated plus maze and open field tests to assess anxiety-like behaviors. Preliminary rotarod and open field tests demonstrated that 2.5 mg/kg SNP had no effect on motor performance. Acute MK-801 treatment induced both cognitive deficits and anxiety. Co-administration of SNP (2.5 mg/kg) failed to improve these schizophrenia-like abnormalities. Sodium nitroprusside appears unable to improve schizophrenia-like symptoms and cognitive deficits induced by MK-801, inconsistent with the effectiveness of SNP as an adjunct therapy for anxiety disorders and working memory impairments in schizophrenia patients. Future studies are required to define an effective dose range for SNP monotherapy and adjunct therapy in different rodent models.